Bisphosphonate vs Denosumab: Which Osteoporosis Treatment Is Right for You?

How Bisphosphonates and Denosumab Work

Both drug classes reduce bone resorption, but they reach osteoclasts through entirely different pathways. Understanding these mechanisms explains why their clinical profiles diverge on discontinuation, renal safety, and long-term bone quality.

Bisphosphonate Mechanism

Bisphosphonates are pyrophosphate analogs that bind directly to hydroxyapatite on bone surfaces. When osteoclasts ingest bisphosphonate-laden bone mineral during resorption, the drug disrupts the mevalonate pathway inside the cell, triggering osteoclast apoptosis [1]. Because the drug embeds in the mineral matrix, its skeletal half-life spans years. Alendronate remains detectable in bone for over a decade after the last dose [2]. This mineral-binding property is why bisphosphonates offer a "residual effect" that persists during drug holidays.

Denosumab Mechanism

Denosumab (Prolia) is a fully human IgG2 monoclonal antibody that binds RANKL, the signaling molecule osteoblasts use to activate osteoclasts. By intercepting RANKL before it reaches the RANK receptor, denosumab prevents osteoclast maturation, activation, and survival [3]. The antibody circulates in serum with a half-life of approximately 25 to 28 days and does not accumulate in bone mineral. Once serum levels decline after a missed or final dose, RANKL signaling rebounds sharply, producing a surge of osteoclast activity that can exceed pre-treatment levels.

Why the Mechanism Matters Clinically

The mineral-binding trait of bisphosphonates means bone retains drug even after you stop taking it. Denosumab leaves no skeletal reservoir. This single pharmacokinetic difference drives the most consequential clinical distinction between the two classes: rebound bone loss after denosumab discontinuation [4].

Fracture Reduction: Head-to-Head Evidence

Fracture prevention is the outcome that matters. Both classes have strong randomized trial data, though direct head-to-head fracture trials remain limited.

Denosumab: The FREEDOM Trial

In the FREEDOM trial (N=7,868), denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo in postmenopausal women with T-scores between −2.5 and −4.0 [3]. The extension study followed participants for 10 years, with cumulative vertebral fracture incidence remaining low at 0.90 to 1.86 per 100 participant-years [5].

Zoledronic Acid: The HORIZON-PFT Trial

The HORIZON Key Fracture Trial (N=7,765) tested annual intravenous zoledronic acid 5 mg against placebo over 3 years. Vertebral fractures fell by 70%, hip fractures by 41%, and nonvertebral fractures by 25% [6]. These reductions are statistically comparable to denosumab, though cross-trial comparisons carry inherent limitations.

Oral Bisphosphonates: FIT and VERT Trials

Alendronate reduced vertebral fractures by 47% and hip fractures by 51% in the Fracture Intervention Trial (FIT; N=6,459) over 3 to 4 years [2]. Risedronate showed a 41% vertebral fracture reduction in the VERT-NA trial (N=2,458) [7]. Oral agents show slightly smaller effect sizes than IV zoledronic acid or denosumab for vertebral fractures, likely reflecting adherence gaps with weekly or monthly dosing.

BMD Gains: Where Denosumab Pulls Ahead

Bone mineral density is a surrogate marker, not an endpoint, but regulatory agencies and guidelines use it to gauge treatment response. Denosumab consistently produces larger BMD increases than bisphosphonates.

Direct Comparison Data

The DECIDE trial (N=1,189) randomized postmenopausal women to denosumab 60 mg every 6 months or alendronate 70 mg weekly. At 12 months, denosumab increased total hip BMD by 3.5% versus 2.6% for alendronate, and lumbar spine BMD by 5.3% versus 4.2% [8]. The difference reached statistical significance at all measured skeletal sites.

STAND Trial: Switching From Alendronate

In the STAND study (N=504), women who switched from alendronate to denosumab gained an additional 1.9% at the total hip and 3.0% at the lumbar spine over 12 months compared to those who continued alendronate [9]. This trial established that denosumab can augment BMD beyond the ceiling that oral bisphosphonates reach.

Long-Term BMD Trajectory

Over 10 years in the FREEDOM extension, denosumab produced cumulative lumbar spine BMD gains of 21.7% and total hip gains of 9.2% from baseline [5]. No therapeutic plateau appeared. Bisphosphonates, by contrast, typically reach a BMD plateau by years 3 to 5.

The Denosumab Discontinuation Problem

This is the single most important clinical consideration separating the two classes. Stopping denosumab without a transition plan creates a dangerous rebound effect.

What Happens After Stopping

A 2017 analysis published in the Journal of Bone and Mineral Research documented that bone turnover markers spike to above pre-treatment levels within 3 to 6 months of the last denosumab injection [4]. Lumbar spine BMD losses of 6 to 7% within the first year off therapy have been reported. Multiple case series identified clusters of vertebral fractures (sometimes 5 or more compression fractures in a single patient) occurring 7 to 18 months after discontinuation [10].

Who Is Most at Risk

Patients who received denosumab for longer durations and those with pre-existing vertebral fractures face the highest rebound risk. The European Calcified Tissue Society (ECTS) released a position statement in 2017 warning that "discontinuation of denosumab should never occur without a plan for subsequent antiresorptive therapy" [10].

The Bisphosphonate Bridge

Current expert consensus recommends transitioning to an oral or IV bisphosphonate within 6 months of the last denosumab dose. A single infusion of zoledronic acid given 6 months after the final denosumab injection is the most studied transition protocol, though the optimal timing remains under investigation [10]. Some patients still lose BMD despite the bridge, making the initial choice between denosumab and a bisphosphonate clinically consequential.

Renal Safety: A Clear Differentiator

Bisphosphonates undergo renal excretion. Denosumab does not. This distinction determines which drug is appropriate for patients with chronic kidney disease.

Bisphosphonate Renal Restrictions

Alendronate and risedronate are contraindicated when creatinine clearance falls below 30 to 35 mL/min. Zoledronic acid carries an FDA black-box, adjacent warning for acute kidney injury, particularly in patients with pre-existing renal impairment or dehydration [6]. Serum creatinine should be measured before each annual infusion.

Denosumab in CKD

Because denosumab is cleared by the reticuloendothelial system rather than the kidneys, it carries no renal contraindication [3]. However, patients with CKD stages 4 to 5 (eGFR <30 mL/min/1.73 m²) face a high risk of severe hypocalcemia after denosumab injection and require close monitoring of serum calcium, phosphorus, and vitamin D levels [11]. Hypocalcemia in this population can be prolonged and clinically significant.

Side Effect Profiles Compared

Both classes are generally well tolerated. The rare but serious adverse events differ between them.

Bisphosphonate-Specific Risks

Oral bisphosphonates cause esophageal irritation in approximately 1 to 2% of patients. Alendronate must be taken on an empty stomach with a full glass of water, followed by 30 minutes of upright posture. This requirement drives a high real-world discontinuation rate: roughly 50% of patients stop oral bisphosphonates within the first year [12]. Atypical femoral fractures (AFFs) affect an estimated 3.2 to 100 per 100,000 person-years with prolonged use beyond 5 years, according to an American Society for Bone and Mineral Research task force report [13]. Osteonecrosis of the jaw (ONJ) occurs at a rate of approximately 1 in 10,000 to 100,000 patient-years at osteoporosis doses [13].

Denosumab-Specific Risks

Denosumab does not cause GI side effects. The injection-site reaction rate in FREEDOM was low (0.8%). Hypocalcemia is uncommon in patients with normal renal function but can be severe in CKD. ONJ and AFF rates appear comparable to bisphosphonates at osteoporosis doses [3]. The FREEDOM extension reported a cumulative AFF rate of 0.8 per 10,000 participant-years through year 10 [5]. Cellulitis and skin infections (eczema, dermatitis) occurred slightly more often with denosumab than placebo in early trials, though this signal did not persist in long-term data.

Alendronate vs Zoledronic Acid: Choosing Within the Bisphosphonate Class

Not all bisphosphonates are interchangeable. Alendronate and zoledronic acid represent the two most prescribed options, and they differ on efficacy, adherence, and route.

Efficacy Differences

Zoledronic acid is the most potent bisphosphonate available. Its 70% vertebral fracture reduction in HORIZON-PFT exceeds alendronate's 47% reduction in FIT, though again, cross-trial comparison has limitations [2][6]. Network meta-analyses suggest zoledronic acid provides a modest additional benefit at the hip compared with oral agents [14].

Adherence and Convenience

Annual IV dosing eliminates the daily or weekly adherence burden. A retrospective cohort study published in Osteoporosis International found that 12-month persistence with zoledronic acid was 72% versus 40% for oral bisphosphonates [12]. For patients who cannot tolerate oral formulations or have poor adherence, IV zoledronic acid is the preferred bisphosphonate.

Post-Infusion Reaction

Approximately 30% of patients experience an acute-phase reaction (fever, myalgia, arthralgia) within 24 to 72 hours of their first zoledronic acid infusion. The reaction is self-limiting, responds to acetaminophen, and typically does not recur with subsequent infusions [6].

Anabolic Agents: Where Forteo and Evenity Fit

Bisphosphonates and denosumab are antiresorptive. A separate class of drugs builds new bone. Anabolic agents are recommended first-line for patients at very high fracture risk per the 2020 Endocrine Society guideline update [15].

Teriparatide (Forteo) and Abaloparatide (Tymlos)

Teriparatide is a recombinant parathyroid hormone fragment (PTH 1-34) given as a daily subcutaneous injection for up to 2 years. In the Fracture Prevention Trial (N=1,637), teriparatide reduced vertebral fractures by 65% and nonvertebral fractures by 53% compared with placebo [16]. Abaloparatide, a PTH-related protein analog, showed an 86% vertebral fracture reduction and a 43% nonvertebral fracture reduction in the ACTIVE trial (N=2,463) over 18 months [17].

Dr. Felicia Cosman, professor of clinical medicine at Columbia University, has stated: "For patients who have already fractured or who have very low T-scores, starting with an anabolic agent and then transitioning to an antiresorptive produces better outcomes than starting with a bisphosphonate alone" [15].

Romosozumab (Evenity) vs Teriparatide

Romosozumab is a sclerostin inhibitor with a dual mechanism: it stimulates bone formation and simultaneously reduces resorption. In the ARCH trial (N=4,093), romosozumab for 12 months followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone over 24 months [18]. The STRUCTURE trial (N=436) directly compared romosozumab against teriparatide in patients transitioning from bisphosphonates and found significantly greater total hip BMD gains with romosozumab at 12 months (2.6% vs 0.7%) [19].

Romosozumab carries a boxed warning for cardiovascular risk. It is contraindicated in patients who have had a myocardial infarction or stroke within the preceding 12 months [18].

The Anabolic-First Sequence

The 2020 Endocrine Society guideline recommends that patients at "very high" fracture risk (recent fracture within 2 years, T-score ≤ −3.0, or fractures on antiresorptive therapy) receive 1 to 2 years of anabolic therapy followed by an antiresorptive agent [15]. This "build first, preserve second" strategy produced a 66% lower vertebral fracture rate compared with the traditional antiresorptive-first approach in the VERO trial, which compared teriparatide against risedronate directly (N=1,360) [20].

The American Association of Clinical Endocrinologists (AACE) echoed this recommendation: "The old approach of reserving anabolic therapy for patients who fail bisphosphonates delays optimal protection for those most likely to fracture again" [15].

Making the Choice: A Decision Framework

Selecting between a bisphosphonate and denosumab requires weighing five variables: fracture risk severity, renal function, adherence likelihood, treatment duration expectations, and cost.

When Bisphosphonates Are Preferred

A bisphosphonate (especially zoledronic acid) is the better first-line choice for patients with moderate fracture risk, normal renal function, and a desire for eventual drug holiday. The residual skeletal effect after discontinuation provides a safety margin that denosumab lacks. Generic alendronate at $4 to 15 per month also makes it the most cost-effective option [12].

When Denosumab Is Preferred

Denosumab is preferred for patients with CKD stage 3b, 5 (where bisphosphonates are contraindicated), those who cannot tolerate oral bisphosphonates, and those who need maximal BMD recovery (e.g., after prolonged glucocorticoid use). The twice-yearly injection schedule suits patients with adherence challenges. However, prescribers must commit to indefinite therapy or a structured bisphosphonate transition plan [10].

When Anabolic Therapy Comes First

Patients who present with a recent vertebral or hip fracture, a T-score at or below −3.0, or multiple risk factors should receive romosozumab (12 months) or teriparatide/abaloparatide (18 to 24 months) before transitioning to a bisphosphonate or denosumab for maintenance [15].

Monitoring and Follow-Up

Treatment response monitoring follows a standard schedule regardless of which antiresorptive is chosen. DXA scans should be repeated 2 years after starting therapy per the 2024 AACE osteoporosis guideline [15]. A BMD decline of ≥5% at the lumbar spine or ≥4% at the total hip despite treatment warrants investigation for secondary causes, poor absorption (for oral bisphosphonates), or medication non-adherence.

Bone Turnover Markers

Serum CTX (C-telopeptide) can confirm antiresorptive effect within 3 to 6 months. A CTX level that remains elevated above the pre-treatment baseline suggests treatment failure or non-adherence. P1NP (procollagen type 1 N-terminal propeptide) is the preferred formation marker for monitoring anabolic therapy response [15].

Duration-Based Reviews

At the 3-year mark for IV zoledronic acid and the 5-year mark for oral bisphosphonates, clinicians should reassess fracture risk. Patients who are no longer at high risk may be candidates for a drug holiday of 2 to 3 years with annual DXA and CTX monitoring [13]. Denosumab does not have a recommended drug holiday. Reassessment focuses on transition planning rather than discontinuation.

Patients receiving denosumab who wish to stop should have zoledronic acid 5 mg IV administered 6 months after the last Prolia injection, with DXA and bone turnover markers checked 6 to 12 months later to confirm BMD stability [10].